Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ADDERALL XR 10 vs ADDERALL 12.5
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Adderall XR 10 contains a mixture of amphetamine salts, which are central nervous system stimulants. The dextroamphetamine and levoamphetamine components increase synaptic concentrations of dopamine and norepinephrine by inhibiting their reuptake and promoting their release from presynaptic terminals. This action leads to enhanced neurotransmission in the prefrontal cortex and other brain regions involved in attention and executive function.
Adderall 12.5 is a combination of dextroamphetamine and amphetamine. It increases the levels of dopamine and norepinephrine in the central nervous system by inhibiting their reuptake and promoting their release from presynaptic neurons.
Attention Deficit Hyperactivity Disorder (ADHD),Narcolepsy (off-label)
Attention deficit hyperactivity disorder (ADHD),Narcolepsy (off-label)
10 mg orally once daily in the morning; maximum dose 40 mg/day.
5-60 mg orally once or twice daily; immediate-release: initial 5 mg once or twice daily, increase by 5 mg weekly; extended-release: initial 20 mg once daily in the morning, increase by 10 mg weekly.
Dexamphetamine: 10-13 hours in adults (children: 6-8 hours); levoamphetamine: 13-16 hours; clinically, steady-state achieved in approximately 3 days, with twice-daily dosing maintaining therapeutic levels
The terminal elimination half-life of d-amphetamine is approximately 10–13 hours in adults (range 9–14 h) and 6–8 hours in children. Clinical context: Typically allows twice-daily dosing; extended-release formulations provide 8–12 hours of effect.
Amphetamine is primarily metabolized by hepatic CYP2D6 to 4-hydroxyamphetamine, which is further conjugated. Minor pathways include N-dealkylation and deamination. The drug has a half-life of approximately 10-13 hours.
Amphetamine and dextroamphetamine are extensively metabolized in the liver via CYP2D6 and other pathways. The primary metabolites are 4-hydroxyamphetamine and 4-hydroxynorephedrine.
Renal (approximately 30-40% as unchanged amphetamine, remainder as metabolites, including deaminated and oxidized products; urinary p H-dependent elimination: acidic p H increases renal clearance, alkaline p H decreases renal clearance; negligible biliary/fecal elimination)
Approximately 30% of the dose is excreted unchanged in urine; the remainder is metabolized primarily via deamination and oxidation. Renal elimination of unchanged amphetamine is p H-dependent: acidic urine increases elimination, alkaline urine decreases it. Fecal excretion accounts for <5%.
15-40% bound to plasma proteins, primarily albumin; lower binding in patients with hepatic impairment
Approximately 15–20% bound to plasma proteins, primarily albumin.
3.0-4.5 L/kg for total amphetamine; high tissue distribution (brain, lungs, kidneys); enters CNS via passive diffusion and active transport
Mean volume of distribution is 3.5–4.6 L/kg, indicating extensive tissue distribution. Clinical meaning: Large Vd reflects sequestration in tissues (including brain), contributing to prolonged presence.
Oral: quantitative absorption with 90-100% bioavailability of the total amphetamine content; food does not affect overall absorption but may delay peak concentrations with high-fat meals
Oral bioavailability is highly variable, ranging from 75–100% for immediate-release tablets; food does not significantly affect overall absorption but may delay time to peak concentration. Extended-release capsules have bioavailability approximately 96% relative to immediate-release.
GFR 15-29 m L/min: reduce dose by 50%; GFR <15 m L/min: not recommended.
GFR 15-29 m L/min: reduce dose to 50% of usual; GFR <15 m L/min: use 50% of usual dose; hemodialysis: not removed, avoid use.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: avoid use.
Child-Pugh A: no adjustment; Child-Pugh B: use 50% of usual dose; Child-Pugh C: avoid use.
Children 6-17 years: starting dose 5 mg once daily; increase by 5 mg weekly based on response; maximum 30 mg/day.
Immediate-release: 3-5 years: initial 2.5 mg once daily, increase by 2.5 mg weekly up to 40 mg/day; 6+ years: initial 5 mg once or twice daily, increase by 5 mg weekly up to 40 mg/day. Extended-release: 6-12 years: initial 10 mg once daily, increase by 10 mg weekly up to 30 mg/day; 13-17 years: initial 10 mg once daily, increase by 10 mg weekly up to 40 mg/day.
Starting dose 5 mg once daily; increase cautiously with monitoring for hypertension, agitation, and cognitive effects.
Start at lowest dose (5 mg immediate-release or 10 mg extended-release) and titrate slowly due to increased risk of adverse cardiovascular and CNS effects; monitor for hypertension, tachycardia, and agitation.
WARNING: ABUSE AND DEPENDENCE. CNS stimulants, including Adderall XR, have a high potential for abuse and dependence. Assess the risk of abuse prior to prescribing and monitor for signs of abuse and dependence while on therapy.
Adderall has a high potential for abuse and dependence. Prolonged use may lead to drug dependence. Misuse may cause sudden death or serious cardiovascular adverse events.
Serious cardiovascular events, including sudden death in patients with pre-existing structural cardiac abnormalities; blood pressure and heart rate increases; psychiatric adverse reactions (e.g., exacerbation of psychosis, mania, aggression); seizures; serotonin syndrome if combined with serotonergic drugs; long-term growth suppression in children; peripheral vasculopathy including Raynaud's phenomenon; potential for abuse and dependence.
Risk of abuse and dependence,Serious cardiovascular events including sudden death, stroke, and myocardial infarction,Blood pressure and heart rate increases,Psychiatric adverse events including exacerbation of pre-existing psychosis, mania, or aggression,Seizures in patients with seizure disorders,Visual disturbances,Growth suppression in children,Peripheral vasculopathy including Raynaud's phenomenon,Serotonin syndrome risk when used with serotonergic drugs
Hypersensitivity to amphetamine or any component of the formulation; patients with advanced arteriosclerosis, symptomatic cardiovascular disease, moderate to severe hypertension, hyperthyroidism, glaucoma; agitated states; history of drug abuse; during or within 14 days following MAOI therapy.
Known hypersensitivity to amphetamine products or other sympathomimetic amines,Concomitant use with MAOIs or within 14 days of MAOI therapy,Glaucoma,Hyperthyroidism,Agitated states,History of drug abuse,Cardiovascular disease including moderate to severe hypertension, advanced arteriosclerosis, symptomatic cardiovascular disease, or tachyarrhythmias
Take ADDERALL XR with or without food. However, high-fat meals may delay absorption and reduce peak concentrations. Avoid consumption of acidic foods or beverages (e.g., citrus fruits, fruit juices, cola) within 1 hour before or after dosing, as acidity can decrease absorption. Vitamin C (ascorbic acid) and other acidifying agents can reduce efficacy; conversely, alkalizing agents (e.g., antacids, sodium bicarbonate) may potentiate effects.
Avoid acidic foods and beverages (e.g., citrus fruits, soda) within 1 hour of administration as they may decrease absorption. High-fat meals may delay absorption of extended-release formulations. Avoid caffeine and other stimulants. Grapefruit juice may increase amphetamine levels.
Pregnancy Category C. First trimester: Limited human data; animal studies show increased risk of cardiovascular malformations (ventricular septal defects) and neural tube defects at high doses. Second trimester: Potential for reduced fetal growth and premature delivery. Third trimester: Risk of neonatal withdrawal syndrome (irritability, dysphoria, tremor, hypertonia) and preterm birth.
First trimester: Increased risk of congenital malformations, particularly cardiovascular defects (e.g., septal defects) and oral clefts based on amphetamine exposure. Second and third trimesters: risk of preterm delivery, low birth weight, and neonatal withdrawal syndrome (irritability, feeding difficulties, respiratory distress). Premature delivery and growth restriction have been reported.
Contraindicated during breastfeeding. Amphetamine is excreted into human milk; M/P ratio approximately 3.5. Infant exposure estimated at 4-8% of maternal weight-adjusted dose. Reported adverse effects in infants include irritability, poor feeding, and sleep disturbances.
Contraindicated due to potential for infant toxicity. M/P ratio not established; amphetamine is excreted into breast milk in small amounts but may accumulate in breastfeeding infants. Adverse effects include irritability, poor feeding, and decreased weight gain.
Increased clearance during 2nd and 3rd trimesters (hepatic induction) may require dose escalation. Postpartum, clearance returns to nonpregnant levels, requiring dose reduction to avoid toxicity. Individualize dosing based on clinical response and tolerability.
Pharmacokinetics altered: increased hepatic metabolism and renal clearance in pregnancy may reduce amphetamine exposure; however, safety data do not support dose adjustment. Use lowest effective dose only if necessary; consider alternative non-amphetamine therapies.
ADDERALL XR (mixed amphetamine salts extended-release) 10 mg is a CNS stimulant indicated for ADHD. Initiate at 10 mg once daily in the morning; titrate in 5-10 mg increments weekly. Swallow capsules whole, or sprinkle contents on applesauce for patients unable to swallow. Avoid afternoon doses to prevent insomnia. Monitor for hypertension, tachycardia, and growth suppression in children. Abuse potential is high; use with caution in patients with history of substance abuse. Contraindicated in glaucoma, hyperthyroidism, agitated states, MAOI use within 14 days, and structural cardiac abnormalities.
ADDERALL 12.5 mg is a fixed-dose combination of amphetamine and dextroamphetamine. Monitor for cardiovascular events, especially in patients with pre-existing heart conditions. Onset of action occurs within 30-60 minutes; duration of action is approximately 4-6 hours. Avoid late afternoon doses to prevent insomnia. Use with caution in patients with a history of drug abuse. May cause growth suppression in children; monitor height and weight. Do not crush or chew extended-release capsules.
Take exactly as prescribed once daily in the morning with or without food.,Do not chew or crush the capsule; you may open it and sprinkle the beads on a spoonful of applesauce, then swallow immediately without chewing.,Avoid taking in the afternoon or evening as it may cause difficulty sleeping.,Do not stop abruptly without consulting your doctor; sudden discontinuation may cause withdrawal symptoms.,Report any chest pain, palpitations, shortness of breath, or fainting to your doctor.,This medication has a high potential for abuse; keep in a safe place and do not share with others.,Avoid alcohol and illicit drugs while taking this medication.,Notify your doctor if you have a history of drug dependence, anxiety, bipolar disorder, or seizures.,For patients with ADHD, it may improve focus, attention, and impulse control.,Store at room temperature away from moisture and heat.
Take exactly as prescribed; do not increase dose without consulting your doctor.,Swallow the capsule whole; do not chew, crush, or open it.,Avoid alcohol while taking this medication.,Do not drive or operate machinery until you know how this medication affects you.,Report any chest pain, shortness of breath, or fainting to your doctor immediately.,Store at room temperature away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ADDERALL XR 10 vs ADDERALL 12.5, answered by our medical review team.
ADDERALL XR 10 is a CNS Stimulant that works by Adderall XR 10 contains a mixture of amphetamine salts, which are central nervous system stimulants. The dextroamphetamine and levoamphetamine components increase synaptic concentrations of dopamine and norepinephrine by inhibiting their reuptake and promoting their release from presynaptic terminals. This action leads to enhanced neurotransmission in the prefrontal cortex and other brain regions involved in attention and executive function.. ADDERALL 12.5 is a CNS Stimulant that works by Adderall 12.5 is a combination of dextroamphetamine and amphetamine. It increases the levels of dopamine and norepinephrine in the central nervous system by inhibiting their reuptake and promoting their release from presynaptic neurons.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ADDERALL XR 10 and ADDERALL 12.5 depend on the specific clinical indication. These are both CNS Stimulant agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ADDERALL XR 10 is: 10 mg orally once daily in the morning; maximum dose 40 mg/day.. The standard adult dose of ADDERALL 12.5 is: 5-60 mg orally once or twice daily; immediate-release: initial 5 mg once or twice daily, increase by 5 mg weekly; extended-release: initial 20 mg once daily in the morning, increase by 10 mg weekly.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ADDERALL XR 10 and ADDERALL 12.5 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ADDERALL XR 10 is classified as Category C. Pregnancy Category C. First trimester: Limited human data; animal studies show increased risk of cardiovascular malformations (ventricular septal defects) and neural tube defects a. ADDERALL 12.5 is classified as Category C. First trimester: Increased risk of congenital malformations, particularly cardiovascular defects (e.g., septal defects) and oral clefts based on amphetamine exposure. Second and th. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.